Global TNF Biosimilars Market

Report ID : 1072 | Published : 2021-07-23 | Pages: 140 | Format: PDF/EXCEL

Tumor necrosis factors are a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spondilitis They are also called TNF blockers. Currently only five TNF are approved which include humira (adalimumab), remicade (infliximab), cimzia (Certolizumab pegol), enbrel (etanercept), and simponi (golimumab). Humira is the king and bestselling drug of the century due to high clinical efficacy and is approved for multiple indications. Entry of biosimilar in the market, major patent expiry of blockbuster drug, and strong ongoing clinical pipeline of biosimilar has boosted the growth of TNF biosimilar market. Moreover, the rising incidence and prevalence of rheumatic disease and switching trends from traditional treatment to biologic therapy have increased the growth of the market. However, stringent government regulation and entry of other promising therapy in the market hamper the growth of the market.
The global TNF biosimilar market is segmented by drug, distribution channel, and geography. On the basis of treatment the global market is further sub segmented into adalimumab biosimilar, infliximab biosimilar, certolizumab biosimilar, etanercept biosimilar, and golimumab biosimilar. Infliximab biosimilar segment followed by etanercept biosimilar segment is expected to hold significant share of the market due to early patent expiry and entry of biosimilars like erie Etanercept-szzs and Infliximab-dyyb into the major market like Europe and United States. Humira is protected with more than 100 patents in US which make the entry of biosimilars complicated in the US market however, biosimilar of adalimumab is expected to launch in the US by 2023 and in Europe in 2018 which drives the growth of the market during forecast period. TNF Inhibitors market is already saturated thus certolizumab biosimilar and golimumab biosimilar segments are expected to hold minimal share of the market due to late entry of biosimilars in the market. On the basis of distribution channel the global market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy segment dominates the global market followed by retail pharmacy and online pharmacy. Online pharmacy segment is expected to grow at high CAGR due to the increase in number internet user and ease of use.
At regional level, the global TNF biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by North America is major contributor for the global TNF biosimilar market. This is because strong ongoing clinical pipeline of biosimilars, increasing research and drug development activities, presence of major players, and increase in demand for biosimilars propels the growth of the market in the region. Asia Pacific is the third promising revenue contributor which is expected to grow at a rapid pace in upcoming year. Countries such as Japan, India, and China are major contributors to this market. Emerging and colossal population base countries such as China and India offer tremendous market opportunities for the TNF biosimilar market. Entry of biosimilar will increase patient affordability and accessibility which in turn increase in consumption of TNF in low-income countries.
Some of the market players leading the global TNF biosimilars market include Amgen, Sandoz, Boehringer Ingelheim, Pfizer, Samsung Bioepis, Coherus Biosciences, Celltrion, Nichi-Iko, and other prominent players.

  • Amgen
  • Sandoz
  • Boehringer Ingelheim
  • Pfizer
  • Samsung Bioepis
  • Coherus Biosciences
  • Celltrion
  • Nichi-Iko
  • Other Prominent Player with Pipeline Product Portfolio

Global TNF Biosimilars Market Outlook (Revenue, US$ Mn, 2019 – 2030), by Drug

  • Adalimumab biosimilar
  • Infliximab biosimilar
  • Certolizumab biosimilar
  • Etanercept biosimilar
  • Golimumab biosimilar

Global TNF Biosimilars Market Outlook (Revenue, US$ Mn, 2019 – 2030), by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global TNF Biosimilars Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region

  • Europe
    • K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients